男人女人午夜视频免费,免费人妻无码不卡中文字幕系,国产A级三级三级三级,成年无码aⅴ片在线观看

血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)活性蛋白

Active Endothelial protein C receptor (EPCR)

CD201; PROCR; CCCA ;CCD41; BA42O4.2; EPCR; Endothelial Protein C Receptor; Cell Cycle, Centrosome-Associated Protein; Activated Protein C Receptor

  • 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)活性蛋白產(chǎn)品包裝(模擬)
  • 血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)活性蛋白產(chǎn)品包裝(模擬)
  • APA022Hu02.jpgFigure. SDS-PAGE
  • Certificate通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

活性實(shí)驗(yàn)

Endothelial protein C receptor (EPCR) also known as CD201, is a transmembrane glycoprotein expressed on vascular endothelial cells and functions as a negative regulator of thrombosis. It is expressed most strongly in the endothelial cells of arteries and veins in heart and lung. Mature human EPCR consists of a 193?amino acid (aa) extracellular domain (ECD), a 21?aa transmembrane segment, and a 7?aa cytoplasmic tail. Within the ECD, human EPCR shares 63%?and 66%?aa sequence identity with mouse and rat EPCR, respectively. EPCR inhibits thrombosis through its interactions with Protein?C, activated Protein C (APC), and Coagulation Factors VII, and VIIa. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human EPCR and recombinant rat Coagulation Factor VII (F7). Briefly, EPCR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to F7-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-EPCR pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human EPCR and recombinant rat F7 was shown in Figure 1, the EC50?for this effect is 0.06 ug/mL.

用法

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

儲(chǔ)存

避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。

相關(guān)產(chǎn)品

編號(hào)適用物種:Homo sapiens (Human,人)應(yīng)用(僅供研究使用,不用于臨床診斷!)
APA022Hu02血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)活性蛋白Cell?culture;?Activity?Assays.
RPA022Hu01血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
PAA022Hu01血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)多克隆抗體WB; IHC; ICC; IP.
LAA022Hu71血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)多克隆抗體(生物素標(biāo)記)WB; IHC; ICC.
MAA022Hu22血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)單克隆抗體WB; IHC; ICC; IP.
SEA022Hu血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)Enzyme-linked immunosorbent assay for Antigen Detection.
LMA022Hu血管內(nèi)皮細(xì)胞蛋白C受體(EPCR)等多因子檢測試劑盒(流式熒光發(fā)光法)FLIA Kit for Antigen Detection.

參考文獻(xiàn)

雜志參考文獻(xiàn)
ВЕСТНИК НОВЫХ МЕДИЦИНСКИХ ТЕХНОЛОГИЙСОВЕРШЕНСТВОВАНИЕ ЛЕЧЕБНО-ДИАГНОСТИЧЕСКИХ МЕРОПРИЯТИЙ ПРИ ГРИППЕ ВО ВРЕМЯ БЕРЕМЕННОСТИ[Bulletin: E2015-1]
Experimental and Therapeutic MedicineUnfractionated heparin protects the protein C system against lipopolysaccharide?induced damage in vivo and in vitro[10.3892/etm.2017.5236]
Biomed PharmacotherEffects and mechanisms of PSS-loaded nanoparticles on coronary microcirculation dysfunction in streptozotocin-induced diabetic cardiomyopathy rats[Pubmed: 31715373]
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINEEffect of Nitinol on Metabolic and Coagulation Activity of Endothelial Cells Culture[34542754]